JUNO - Juno Therapeutics, Inc.

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Moody'slast month

    Washington Health Care Facilities Auth -- Moody's upgrades Fred Hutchinson Cancer Research Center (WA) to A2 from A3; outlook stable

    Moody's Investors Service has upgraded Fred Hutchinson Cancer Research Center's (WA) (FHCRC or Fred Hutch) issuer and long-term debt ratings to A2 from A3. The upgrade to A2 reflects the dramatic improvement in Fred Hutch's unrestricted liquidity and growth in cash and investments expected to remain strong. During fiscal 2018 ending June 30, Fred Hutch received substantial funds related to its holdings of Juno Therapeutics.

  • Celgene Plunges On Report Its Head Of Mergers Quietly Exited In April
    Investor's Business Daily11 months ago

    Celgene Plunges On Report Its Head Of Mergers Quietly Exited In April

    Celgene plunged to another four-year low Monday on a report that an executive in charge of business development quietly retired in mid-April.

  • Celgene Corporation (CELG) Q1 2018 Earnings Conference Call Transcript
    Motley Fool11 months ago

    Celgene Corporation (CELG) Q1 2018 Earnings Conference Call Transcript

    CELG earnings call for the period ending March 31, 2018.

  • Investopedia11 months ago

    Celgene's 3 Key Financial Ratios (CELG)

    Celgene Corporation (NASDAQ: CELG) is an integrated biotechnology company that develops and sells therapies for the treatment of oncology and inflammatory diseases through gene and protein regulation. Celgene is most known for its blockbuster drug Revlimid, which treats multiple myeloma. Despite significant growth in this disease around the world, Celgene shows too much reliance on a single drug, and the company undertook a number of acquisitions to diversify its drug portfolio with immuno-oncology therapies.